Normalizing glycated albumin reduces increased urinary collagen IV and prevents renal insufficiency in diabetic db/db mice

Metabolism: Clinical and Experimental

Volumn 51, Issue 7, 2002, Pages 901-905

  Cohen, Margo P ^a   Hud, Elizabeth ^a   Shea, Elizabeth ^a   Shearman, Clyde W ^a  

^a The Science Center Philadelphia   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 4; COMPOUND 22CPPA; GLYCOSYLATED ALBUMIN; PROSTAGLANDIN SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ALBUMIN BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL NUCLEUS MATRIX; COLLAGEN METABOLISM; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG INHIBITION; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION; HYPERGLYCEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TUBULE EXCRETION; MALE; MESANGIUM; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; URINE LEVEL;

EID: 0036068029     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1053/meta.2002.33359     Document Type: Article

References (49)

1. Extracellular matrix proteins as early markers in diabetic nephropathy
2. Urinary type IV collagen as a marker of early diabetic nephropathy
3. Significance of urinary type IV collagen in patients with diabetic nephropathy using a highly sensitive one-step sandwich enzyme immunoassay
4. Type IV collagen as an early marker for diabetic nephropathy in non-insulin dependent diabetes mellitus
5. Serum and urinary concentrations of type IV collagen and laminin as a marker of microangiopathy in diabetes
6. Increased collagen IV excretion in diabetes. A marker of compromised filtration function
7. Increased urinary type IV collagen marks the development of glomerular pathology in diabetic db/db mice
8. Microalbuminuria as a predictor of clinical diabetic nephropathy
9. Effect of duration of type 1 diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio
10. Measuring progression of diabetic nephropathy
11. Intact" nephrons as the primary origin of proteinuria in chronic renal disease
12. Amadori glucose adducts modulate cell growth and collagen gene expression
13. Glycated albumin stimulates fibronectin gene expression in glomerular mesangial cells: Involvement of the transforming growth factor-β system
14. Glycated albumin stimulation of PKC-β activity is linked to increased collagen IV in mesangial cells
15. Glycated albumin stimulates TGF-β1 production of PKC activity in glomerular endothelial cells
16. Amelioration of diabetic nephropathy with monoclonal antibodies against glycated albumin
17. Prevention of diabetic nephropathy in db/db mice with glycated albumin antagonists: A novel treatment strategy
18. Prevention of decline in renal function in the db/db mouse
19. Inhibiting albumin glycation ameliorates diabetic nephropathy in the db/db mouse
20. ERK mediates effects of glycated albumin in mesangial cells
21. Anti-glycated albumin therapy ameliorates early retinal microvascular pathology in db/db mice
22. Glycation of human serum albumin. Inhibition by diclofenac
23. Diclofenac binding to albumin and lipoproteins in human serum
24. The non-enzymatic glycosylation of bovine lens proteins by glucosamine and its inhibition by aspirin, ibuprofen and glutathione
25. Aspirin prevents carbamylation of soluble lens proteins and prevents cyanate-induced phase separation opacities in vitro: A possible mechanism by which aspirin could prevent cataract
26. Non-enzymic glycosylation (glycation) of lens proteins by galactose and protection by aspirin and reduced glutathione
27. Synthesis and quantitative structure-activity relationships of diclofenac
28. Improved competitive enzyme-linked immunoassay (ELISA) for albuminuria
29. Diabetes, a new mutant in the mouse
30. Hyperinsulinemia in pre-weanling diabetic mice
31. Studies in the diabetic mutant mouse. Physiological factors associated with alterations in beta cell proliferation
32. Nonenzymatic glycosylation of serum proteins and hemoglobin: Response to changes in blood glucose levels in diabetic rats
33. An interspecies comparison of normal levels of glycosylated hemoglobin and glycosylated albumin
34. Evolution of renal function abnormalities in the db/db mouse that parallels the development of human diabetic nephropathy
35. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal anti-transforming growth factor-β antibody in db/db diabetic mice
36. Serum type IV collagen in diabetic patients at risk for nephropathy
37. Glucose enhances type IV collagen production in cultured rat glomerular mesangial cells
38. Increased extracellular matrix synthesis and mRNA in mesangial cells grown in high-glucose medium
39. High glucose increases diacylglycerol mass and activates protein kinase C in mesangial cell cultures
40. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-β
41. Extracellular signal-regulated kinase mediates stimulation of TGF-β1 and matrix by high glucose in mesangial cells
42. Glomerular basement membrane selective permeability in short-term streptozotocin-induced diabetic rats
43. Immunohistochemical and functional correlations of renal cyclo-oxygenase-2 in experimental diabetes
44. Receptors specific for Amadori modified glycated albumin on murine endothelial cells
45. Binding sites for short-term glycated albumin on peritoneal cells of the rat
46. Expression of fructosyllysine receptors on human monocytes and monocyte-like cell lines
47. Binding and transcytosis of glycoalbumin by the microvascular endothelium of the murine myocardium: Evidence that glycoalbumin behaves as a bifunctional ligand
48. Albumin interacts specifically with a 60 kDa microvascular endothelial glycoprotein
49. Identification of calnexin as a binding protein for Amadori-modified glycated albumin